BRCA1 and BRCA2 in Pancreatic Cancer

BRCA1 and BRCA2 are genes that normally protect cells from becoming cancerous by repairing damaged DNA and keeping cell division under control. When one of these genes carries a harmful change (mutation), that protective function is lost, and the risk of several cancers, including pancreatic cancer, rises. Testing for BRCA1 and BRCA2 in pancreatic cancer matters for two reasons that affect different people: it can open the door to a specific group of targeted drugs called PARP inhibitors for the patient, and, when the mutation is inherited, it has implications for the cancer risk of biological relatives.

This article will help you understand what a BRCA1 or BRCA2 result means on a pathology report or genetic test for pancreatic cancer, why the test is done, how it is performed, and how the result may guide treatment decisions. A central idea runs through the whole article: a BRCA mutation can be either inherited (germline) or present only in the tumor (somatic), and the type determines what the result means for the patient and their family. Because inherited BRCA mutations are an important cause of pancreatic cancer, current guidelines recommend that everyone diagnosed with the most common type of pancreatic cancer be offered testing.

What the test looks for

BRCA1 and BRCA2 testing in pancreatic cancer looks for a harmful change in one of these two DNA-repair genes. Every person is born with two copies of each gene, one from each parent. BRCA1 and BRCA2 are tumor suppressor genes: their normal job is to detect and repair DNA breaks. When one copy is mutated and the second copy is later lost or damaged inside a cell, that cell can no longer repair DNA properly, becomes unstable, and is far more likely to turn into cancer.

BRCA mutations come in two fundamentally different forms, and telling them apart is the key to understanding the result:

Germline mutation (inherited) — A germline mutation was present in the egg or sperm cell at conception and is therefore carried in every cell of the body from birth. A person with a germline BRCA mutation inherited it from a parent and has a 50 percent chance of passing it to each of their children. Germline mutations are the basis of hereditary breast and ovarian cancer (HBOC) syndrome, which also raises the risk of pancreatic cancer, particularly in BRCA2 carriers. They are found through a blood or saliva test, not a tumor sample.
Somatic mutation (acquired) — A somatic mutation arose during a person’s lifetime, only within the cancer cells. It was not inherited and cannot be passed to children. Somatic BRCA mutations are found by testing the tumor tissue. They can still matter for treatment, because they may predict response to PARP inhibitors, but they do not carry the same hereditary implications as germline mutations.

A germline or somatic BRCA mutation is found in roughly 5-8% of pancreatic cancers, with BRCA2 mutations more common than BRCA1 mutations. Closely related genes in the same DNA repair pathway, especially PALB2 and ATM, can have similar effects, which is why molecular testing in pancreatic cancer often examines this group of genes together rather than BRCA1 and BRCA2 alone.

Why is the test done in pancreatic cancer?

BRCA1 and BRCA2 testing in pancreatic cancer is performed because a mutation in one of these DNA repair genes, whether inherited or present only in the tumor, can affect both treatment and family risk. There are three main reasons the test is performed.

To determine eligibility for PARP inhibitor therapy — PARP inhibitors are drugs that exploit a cancer’s inability to repair DNA when BRCA function is lost. In a cell that already cannot repair DNA because BRCA is not working, blocking a second repair pathway called PARP causes so much damage that the cancer cell dies, while normal cells with working BRCA are largely spared. This mechanism is called synthetic lethality. In pancreatic cancer, the PARP inhibitor olaparib is used as maintenance treatment for patients with a germline BRCA mutation whose cancer has not progressed after a period of platinum-based chemotherapy. Knowing the BRCA status is required before this drug can be considered.
To guide chemotherapy decisions — Pancreatic cancers with a BRCA mutation tend to be more sensitive to platinum-based chemotherapy drugs such as oxaliplatin (part of the combination known as FOLFIRINOX) and cisplatin. A BRCA result may therefore inform the choice of chemotherapy.
To identify inherited risk and enable family testing — A germline BRCA mutation means biological relatives may carry the same change. Identifying it allows family members to be offered testing and, if they carry it, to begin appropriate cancer screening or risk-reduction measures.

Who should be tested in pancreatic cancer?

Guidance on BRCA testing in pancreatic cancer is broader than many patients expect. Because inherited BRCA1, BRCA2, and related mutations are a meaningful cause of pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, current guidelines recommend that all patients diagnosed with pancreatic ductal adenocarcinoma be offered germline genetic testing, regardless of age or family history. This is different from some other cancers, where testing is reserved for those with specific risk factors. The reason is that the mutation is common enough, and the treatment and family implications important enough, that testing everyone is worthwhile.

Testing is particularly important to pursue for patients who also have a personal or family history of breast, ovarian, prostate, or pancreatic cancer, or who have Ashkenazi Jewish ancestry, in which certain BRCA founder mutations are more common. If germline testing has not been offered, it is reasonable to ask the oncology team for a referral to a genetic counselor.

How the test is performed

BRCA1 and BRCA2 testing in pancreatic cancer is done in two different ways depending on whether the goal is to find an inherited mutation or a mutation in the tumor. The two approaches use different samples and answer different questions.

Germline testing — Germline BRCA testing is performed on a blood or saliva sample, not on tumor tissue, because it looks for an inherited change carried in every cell of the body. The DNA is sequenced to identify mutations in BRCA1 and BRCA2, often as part of a broader panel that also covers related genes such as PALB2 and ATM. This testing is arranged through a genetic counselor or oncologist, and results generally take a few weeks.
Somatic (tumor) testing — Somatic BRCA testing is performed on the tumor tissue, either the biopsy sample or a surgical specimen, using next-generation sequencing (NGS). It is often part of a comprehensive molecular profile that also reports KRAS and other findings. In some situations, BRCA can also be assessed from a blood sample called a liquid biopsy, which detects tumor DNA in the bloodstream.

An important point connects the two: a somatic BRCA mutation found on tumor testing does not, by itself, tell whether the mutation is also inherited. When a BRCA mutation is found in the tumor, germline testing is usually recommended to determine whether it was inherited, because that answer is what matters for family members.

How results are reported

BRCA1 and BRCA2 results in pancreatic cancer describe whether a harmful change was found in either gene, and germline results are reported using a five-category system from the American College of Medical Genetics. The same categories apply whether testing was done for pancreatic cancer or any other cancer.

Pathogenic variant — A change that is clearly harmful and disrupts the BRCA1 or BRCA2 protein. This is what is usually meant by “testing positive.” It prompts referral to a genetic counselor, consideration of PARP inhibitor therapy, and notification that family members may wish to be tested.
Likely pathogenic variant — A change that is almost certainly harmful based on current evidence. In most cases it is managed the same as a pathogenic variant.
Variant of uncertain significance (VUS) — A change whose effect on the gene is not yet known. A VUS is neither a positive nor a negative result and should not be used to make treatment or risk decisions in either direction. Laboratories reclassify these as more evidence accumulates.
Likely benign variant — A change that is almost certainly harmless. No action is required.
Benign variant or no pathogenic variant detected — No harmful mutation was found in the genes tested. This is a negative result. It reduces, but does not completely eliminate, the chance of an inherited cause, because not every hereditary risk gene is captured by every test.

Tumor (somatic) testing reports are usually phrased more simply as a BRCA1 or BRCA2 mutation being detected or not detected, and the report may note whether the change is known to be significant.

What each result means

What a BRCA1 or BRCA2 result means in pancreatic cancer depends on the type of mutation found and whether it is inherited or only in the tumor.

Pathogenic germline BRCA2 mutation — BRCA2 is the more common inherited cause in pancreatic cancer. It identifies eligibility for PARP inhibitor maintenance therapy with olaparib after platinum-based chemotherapy, may support the use of platinum chemotherapy, and means relatives should be offered testing. BRCA2 carriers also have an increased risk of breast, ovarian, and prostate cancer, which becomes part of long-term care.
Pathogenic germline BRCA1 mutation — Less common than BRCA2 in pancreatic cancer but carries the same main implications: PARP inhibitor eligibility, possible platinum sensitivity, and inherited risk that warrants family testing and attention to breast and ovarian cancer risk.
Somatic BRCA mutation (tumor only) — The mutation is in the cancer cells but was not inherited. It does not increase the patient’s risk of other cancers and cannot be passed to children, but it may still predict response to PARP inhibitors and platinum chemotherapy. Germline testing is usually recommended to confirm the mutation is truly somatic.
Variant of uncertain significance (VUS) — No treatment or risk decisions should be made based on a VUS alone. Genetic counseling is recommended, and the laboratory will update the interpretation if the variant is reclassified.
No pathogenic variant detected (negative) — No harmful BRCA mutation was found. If only BRCA1 and BRCA2 were tested, related genes such as PALB2 and ATM may still be relevant, particularly with a strong family history, and broader testing or genetic counseling may be considered.

The role of genetic counseling

Genetic counseling is strongly recommended before and after germline BRCA testing in pancreatic cancer, because the results reach beyond the patient’s own treatment. A genetic counselor helps assess personal and family history to decide which genes to test, explains in plain language what a positive, negative, or uncertain result means before testing is done, discusses the emotional and family dimensions of an inherited result, and coordinates cascade testing, the process of offering targeted testing to relatives once a specific mutation is identified. The counselor also reviews results if a variant of uncertain significance is later reclassified. This support does not need to delay cancer treatment; the genetic evaluation can proceed alongside the patient’s care.

What happens after BRCA testing?

Once BRCA1 and BRCA2 testing for pancreatic cancer is complete, the results become part of the information the treatment team uses to plan care, and the next steps depend on what is found.

If a pathogenic germline BRCA mutation is found, the oncology team considers whether PARP inhibitor maintenance therapy with olaparib is appropriate after platinum-based chemotherapy, a genetic counselor develops a plan covering the patient’s other cancer risks and family testing, and relatives can be offered cascade testing.
If a somatic BRCA mutation is found in the tumor, germline testing is usually recommended to determine whether it was inherited, and the team assesses eligibility for a PARP inhibitor.
If a variant of uncertain significance is found, no action is taken based on the VUS alone, genetic counseling is recommended, and the laboratory provides updated interpretations if the classification changes.
If the result is negative, the team considers whether related genes, such as PALB2 and ATM, or a broader hereditary assessment is warranted based on personal and family history.

Pancreatic cancer care usually involves a multidisciplinary team that may include a medical oncologist, a surgeon, a radiation oncologist, a gastroenterologist, a pathologist, and a genetic counselor. The medical oncologist typically leads decisions about systemic therapy, including chemotherapy and PARP inhibitor maintenance. Regular imaging and follow-up visits are used to track how the cancer is responding to treatment.

Questions to ask your doctor

Should I have germline BRCA1/2 testing, and does the recommendation to test everyone with pancreatic cancer apply to me?
Was my tumor also tested for a somatic BRCA mutation as part of molecular profiling?
If a BRCA mutation was found, is it inherited (germline) or only in the tumor (somatic)?
Does my BRCA result make me eligible for PARP inhibitor maintenance therapy with olaparib?
Does my BRCA result affect which chemotherapy you would consider, such as a platinum-based combination?
Should I also be tested for related genes such as PALB2 or ATM?
If I have a germline mutation, what does it mean for my risk of other cancers?
Should my family members be tested, and how do I arrange that?
If I received a variant of uncertain significance, what does that mean, and how will I learn if it is reclassified?
Can you refer me to a genetic counselor?